drugset

drugset / Trial / NCT06523153

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

NCT06523153 ↗

Phase 1 Active not recruiting 40 enrolled Invivyd, Inc. Novotech (Australia) Pty Limited · collab

RandomizedSequentialQuadruple-blindOther

Summary

A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants

Timeline

Start: 2024-08-28
Primary completion: 2025-05
Completion: 2025-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VYD2311	Monoclonal antibody	—	Intravenous

Indications